Literature DB >> 8968898

Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance.

Y De Gheldre1, N Maes, F Rost, R De Ryck, P Clevenbergh, J L Vincent, M J Struelens.   

Abstract

Molecular typing was used to investigate an outbreak of infection caused by multidrug-resistant Enterobacter aerogenes (MREA) susceptible only to gentamicin and imipenem in an intensive care unit (ICU). Over a 9-month period, ciprofloxacin-resistant E. aerogenes isolates were isolated from 34 patients, or 4.1% of ICU admissions, compared with a baseline rate of 0.1% in the previous period (P < 0.001). Infection developed in 15 (44%) patients. In vivo emergence of imipenem resistance (MIC, 32 micrograms/ml) of organisms causing deep-seated infection was observed in two (13%) of these patients following prolonged therapy with imipenem and gentamicin. Arbitrarily primed PCR (AP-PCR) analysis with ERIC1R and ERIC2 primers and pulsed-field gel electrophoresis (PFGE) analysis of XbaI macrorestriction patterns concordantly showed that outbreak-associated MREA isolates were clonally related and distinct from epidemiologically unrelated strains. AP-PCR and PFGE showed discrimination indices of 0.88 and 0.98, respectively. Space-time clustering of cases within units suggests that the epidemic-related MREA isolates were transmitted on the hands of the health care personnel. A case-control study and repeated environmental culture surveys failed to identify a common source or procedure associated with transmission. In spite of the early implementation of isolation measures, the incidence of MREA colonization remained stable until all colonized patients were discharged. This study confirms the usefulness of AP-PCR and PFGE analyses for the epidemiological study of E. aerogenes and underscores the difficulty of controlling the spread of multiresistant clones of this organism in the ICU setting. The emergence of imipenem resistance represents a threat because virtually no therapeutic option is available for such strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8968898      PMCID: PMC229529          DOI: 10.1128/jcm.35.1.152-160.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units.

Authors:  F A Manian; L Meyer; J Jenne; A Owen; T Taff
Journal:  Infect Control Hosp Epidemiol       Date:  1996-04       Impact factor: 3.254

2.  Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family enterobacteriaceae.

Authors:  C Neuwirth; E Siebor; J Lopez; A Pechinot; A Kazmierczak
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

Review 3.  DNA fingerprinting of medically important microorganisms by use of PCR.

Authors:  A van Belkum
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 4.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Investigation of outbreaks of Enterobacter aerogenes colonisation and infection in intensive care units by random amplification of polymorphic DNA.

Authors:  A Davin-Regli; P Saux; C Bollet; F Gouin; P De Micco
Journal:  J Med Microbiol       Date:  1996-02       Impact factor: 2.472

6.  Molecular epidemiology of infections due to Enterobacter aerogenes: identification of hospital outbreak-associated strains by molecular techniques.

Authors:  P R Georghiou; R J Hamill; C E Wright; J Versalovic; T Koeuth; D A Watson; J R Lupski
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

7.  Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units.

Authors:  A Davin-Regli; D Monnet; P Saux; C Bosi; R Charrel; A Barthelemy; C Bollet
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

8.  Characterization of nosocomial strains of Enterobacter aerogenes by arbitrarily primed-PCR analysis and ribotyping.

Authors:  F Grattard; B Pozzetto; L Tabard; M Petit; A Ros; O G Gaudin
Journal:  Infect Control Hosp Epidemiol       Date:  1995-04       Impact factor: 3.254

9.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

10.  Consecutive mutations leading to the emergence in vivo of imipenem resistance in a clinical strain of Enterobacter aerogenes.

Authors:  L S Tzouvelekis; E Tzelepi; M E Kaufmann; A F Mentis
Journal:  J Med Microbiol       Date:  1994-06       Impact factor: 2.472

View more
  27 in total

1.  In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.

Authors:  D M Livermore; M W Carter; S Bagel; B Wiedemann; F Baquero; E Loza; H P Endtz; N van Den Braak; C J Fernandes; L Fernandes; N Frimodt-Moller; L S Rasmussen; H Giamarellou; E Giamarellos-Bourboulis; V Jarlier; J Nguyen; C E Nord; M J Struelens; C Nonhoff; J Turnidge; J Bell; R Zbinden; S Pfister; L Mixson; D L Shungu
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Omp35, a new Enterobacter aerogenes porin involved in selective susceptibility to cephalosporins.

Authors:  Charléric Bornet; Nathalie Saint; Lilia Fetnaci; Myrielle Dupont; Anne Davin-Régli; Claude Bollet; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 3.  The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions.

Authors:  M J Struelens
Journal:  BMJ       Date:  1998-09-05

4.  National epidemiologic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 1998.

Authors:  Y De Gheldre; M J Struelens; Y Glupczynski; P De Mol; N Maes; C Nonhoff; H Chetoui; C Sion; O Ronveaux; M Vaneechoutte
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Coexistence of SHV-4- and TEM-24-producing Enterobacter aerogenes strains before a large outbreak of TEM-24-producing strains in a French hospital.

Authors:  H Mammeri; G Laurans; M Eveillard; S Castelain; F Eb
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

6.  Most Enterobacter aerogenes strains in France belong to a prevalent clone.

Authors:  C Bosi; A Davin-Regli; C Bornet; M Mallea; J M Pages; C Bollet
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

7.  Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogs.

Authors:  Hesna Yigit; Gregory J Anderson; James W Biddle; Christine D Steward; J Kamile Rasheed; Lourdes L Valera; John E McGowan; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Molecular epidemiology of an outbreak of Enterobacter cloacae in the neonatal intensive care unit of a provincial hospital in Gauteng, South Africa.

Authors:  W H van Nierop; A G Duse; R G Stewart; Y R Bilgeri; H J Koornhof
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

9.  Successive emergence of extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter aerogenes isolates in a university hospital.

Authors:  M Biendo; B Canarelli; D Thomas; F Rousseau; F Hamdad; C Adjide; G Laurans; F Eb
Journal:  J Clin Microbiol       Date:  2008-01-30       Impact factor: 5.948

10.  Molecular epidemiological study of nosocomial Enterobacter aerogenes isolates in a Belgian hospital.

Authors:  S Jalaluddin; J M Devaster; R Scheen; M Gerard; J P Butzler
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.